iBio Inc. [AMEX: IBIO] slipped around -0.05 points on Tuesday, while shares priced at $0.58 at the close of the session, down -9.06%. The company report on December 22, 2021 that iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022.
– Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin -.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it has adjourned its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) with respect to Proposals 4 and 5.
iBio Inc. stock is now -45.13% down from its year-to-date (YTD) trading value. IBIO Stock saw the intraday high of $0.63 and lowest of $0.57 per share. The company’s 52-week high price is 2.83, which means current price is +2.87% above from all time high which was touched on 02/10/21.
Compared to the average trading volume of 3.80M shares, IBIO reached a trading volume of 3555292 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about iBio Inc. [IBIO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBIO shares is $2.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBIO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on November 29, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on January 22, 2021, representing the official price target for iBio Inc. stock. Previously, the target price had yet another raise to $2.55, while Alliance Global Partners analysts kept a Buy rating on IBIO stock.
The Average True Range (ATR) for iBio Inc. is set at 0.07, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 56.66. The Price to Book ratio for the last quarter was 1.25, with the Price to Cash per share for the same quarter was set at 0.38.
How has IBIO stock performed recently?
iBio Inc. [IBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.13. With this latest performance, IBIO shares dropped by -12.84% in over the last four-week period, additionally sinking by -61.59% over the last 6 months – not to mention a drop of -48.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 35.05, with the RSI for the last a single of trading hit 30.93, and the three-weeks RSI is set at 36.64 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 0.7340, while it was recorded at 0.6369 for the last single week of trading, and 1.1917 for the last 200 days.
iBio Inc. [IBIO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and iBio Inc. [IBIO] shares currently have an operating margin of -1312.15 and a Gross Margin at -63.48. iBio Inc.’s Net Margin is presently recorded at -978.79.
Return on Total Capital for IBIO is now -26.96, given the latest momentum, and Return on Invested Capital for the company is -20.24. Return on Equity for this stock declined to -28.10, with Return on Assets sitting at -19.25. When it comes to the capital structure of this company, iBio Inc. [IBIO] has a Total Debt to Total Equity ratio set at 30.13. Additionally, IBIO Total Debt to Total Capital is recorded at 23.16, with Total Debt to Total Assets ending up at 22.26. Long-Term Debt to Equity for the company is recorded at 29.24, with the Long-Term Debt to Total Capital now at 22.47.
Reflecting on the efficiency of the workforce at the company, iBio Inc. [IBIO] managed to generate an average of -$309,427 per employee. Receivables Turnover for the company is 0.43 with a Total Asset Turnover recorded at a value of 0.02.iBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.00 and a Current Ratio set at 11.10.
Insider trade positions for iBio Inc. [IBIO]
There are presently around $28 million, or 20.80% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: BLACKROCK INC. with ownership of 15,517,020, which is approximately -0.234% of the company’s market cap and around 0.99% of the total institutional ownership; VANGUARD GROUP INC, holding 10,511,607 shares of the stock with an approximate value of $6.65 million in IBIO stocks shares; and STATE STREET CORP, currently with $2.9 million in IBIO stock with ownership of nearly 19.224% of the company’s market capitalization.
Positions in iBio Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 40 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 2,800,613 shares. Additionally, 35 investors decreased positions by around 1,437,000 shares, while 29 investors held positions by with 40,539,579 shares. The mentioned changes placed institutional holdings at 44,777,192 shares, according to the latest SEC report filing. IBIO stock had 17 new institutional investments in for a total of 835,744 shares, while 14 institutional investors sold positions of 550,712 shares during the same period.